jnj-40411813
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01951053)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 2POSITIVE ALLOSTERIC MODULATOR
Metabotropic glutamate receptor 2 positive allosteric modulator
- Metabotropic glutamate receptor 2MODULATOR
GRM2 modulator
Chemistry & pharmacology
Loading structure…
SMILES
CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O- Mol. weight
- 344.89 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3337527 ↗
Also known as
- 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1h)-pyridone
- adx71149
- jnj-40411813
- jnj-40411813
- jnj-40411813
- jnj-40411813
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04836559 | Phase 2 | May 18, 2021 | Janssen Pharmaceutica NV |
| NCT04677530 | Phase 1 | Jan 29, 2021 | Janssen Pharmaceutica NV |
| NCT01582815 | Phase 2 | Sep 1, 2012 | Johnson and Johnson |
| NCT01323205 | Phase 2 | May 1, 2011 | Johnson and Johnson |
| NCT01359852 | Phase 1 | Dec 1, 2010 | Johnson and Johnson |
| NCT01358006 | Phase 1 | Nov 1, 2010 | Johnson and Johnson |
| NCT01932333 | Phase 1 | May 1, 2010 | Johnson and Johnson |
| NCT01932320 | Phase 1 | Feb 1, 2010 | Johnson and Johnson |
| NCT01101659 | Phase 1 | Feb 1, 2010 | Johnson and Johnson |
| NCT01951053 | Phase 1 | Jan 1, 2010 | Johnson and Johnson |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 8 | 8 | 2 | 2010 |
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1